Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 \[anti-PD-1\] therapy, after anti-PD-1 as monotherapy, or after tyrosine kinase inhibitor \[TKI\] therapy). The study will consist of a Screening Period, a Treatment Period, a Treatment Discontinuation Visit, and a Follow-Up Period.
Interventions
DRUGAtezolizumab
Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically documented Stage IIIb or Stage IV NSCLC that has progressed following standard systemic chemotherapy (including if given in combination with anti-PD-1 therapy, after anti-PD-1 as monotherapy, or after TKI therapy). Participants with a previously detected sensitizing epidermal growth factor receptor (EGFR) mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion oncogene must have received targeted therapy (TKI) followed by at least one line of standard systemic chemotherapy prior to receiving atezolizumab. Overall, participants should not have received more than two lines of standard systemic chemotherapy. Participants who have discontinued first-line or second-line therapy due to intolerance are also eligible * The last dose of prior systemic anticancer therapy or targeted therapy must have been administered more than or equal to (≥) 21 days prior to randomization. * The last dose of prior anti-PD-1 therapy must have been administered. Nivolumab must have been discontinued \>= 14 days and pembrolizumab \>= 21 days prior to study treatment initiation, providing that these treatments were not administered in a clinical trial setting. * Measurable disease, as defined by Response Evaluation Criteria for Solid Tumors, Version 1.1 (RECIST v1.1) * Participants with asymptomatic central nervous system (CNS) metastases (treated or untreated), as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic evaluation, are eligible * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 * Life expectancy ≥ 12 weeks * Adequate hematologic and end-organ function * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab * Participants must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and toxicities related to prior anti-PD-1-therapy
Exclusion criteria
* Symptomatic CNS metastases * Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to study treatment initiation * Leptomeningeal disease * Uncontrolled pericardial effusion or ascites requiring recurrent drainage procedures * Pregnant or lactating, or intending to become pregnant during the study * Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome) * Significant cardiovascular disease, such as New York Heart Association cardiac disease ≥ Class III, myocardial infarction within 3 months, unstable arrhythmias, or unstable angina * Significant renal disorder requiring dialysis or indication for renal transplant * Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to study treatment initiation * Major surgical procedure within 4 weeks prior to study treatment initiation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis * Inability to understand the local language(s) for which the EORTC QLQ-LC13 and EQ-5D-5L questionnaires are available * History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation * History of autoimmune disease are allowed if controlled and on stable treatment (i.e., same treatment, same dose) for the last 12 weeks * Prior allogeneic stem cell or solid organ transplantation * History of idiopathic pulmonary fibrosis, including pneumonitis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan * Active tuberculosis * Administration of a live, attenuated vaccine within 4 weeks prior to study treatment initiation * Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies other than anti-PD-1 therapy, including anti-programmed death-ligand 1 therapeutic antibodies * Treatment with systemic immunostimulatory agents (including, but not limited to, interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever is longer, prior to initiation of study treatment * Specifically for participants without autoimmune disease: treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to study treatment initiation, or anticipated requirement for systemic immunosuppressive medications during the trial. For participants with CNS metastases, use of prednisone at a stable dose (or dose equivalent) of \<= 20 mg/day is acceptable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Adverse Events | Baseline up to 4 years | An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unitended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a pharmaceutical product whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as a AEs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Alive 2 Years After Initiation of Treatment | Baseline up to Year 2 | The overall survival (OS) rate at 2 years, was defined as the percentage of participants remaining alive 2 years after initiation of study treatment. |
| Progression-Free Survival (PFS) as Evaluated By the Investigator in Accordance With Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v.1.1) | Baseline up to disease progression or death whichever occurs first (up to 4 years) | PFS was defined as the time (in months) from initiation of study treatment to the first documented disease progression or death from any cause, whichever occurred first. PFS was evaluated by the investigator according to RECIST v1.1. |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a Visual Analogue Scale (VAS) that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the mobility item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'. |
| EQ-5D-5L Questionnaire - Self-Care Item | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the self-care item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'. |
| EQ-5D-5L Questionnaire - Usual Activities Item | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the usual activities item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'. |
| EQ-5D-5L Questionnaire - Pain/Discomfort Item | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the pain/discomfort item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'. |
| EQ-5D-5L Questionnaire - Anxiety/Depression Item | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the anxiety/depression item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'. |
| Overall Survival (OS) | Baseline up to death (up to 4 years) | OS was defined as the time (in months) from initiation of study treatment to death from any cause. |
| European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Day 1 of first 3 cycles (21-day cycle), then every 6 weeks for 48 weeks; thereafter every 9 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EORTC QLQ-LC13 consisted of 13 items that address key lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related adverse effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. The dysphagia scale is multi-item, while the rest are single-item scales. The scales are linearly transformed so that each score has a range from 0 to 100. A high scale score represents a higher response level (e.g. a high score for global health status represents a high QoL). A high score for the symptom scale represents a high level of symptoms. A \>=10-point change in the EORTC scale score was perceived by participants as clinically significant. Values presented after baseline represent the change from baseline. |
| Progression-Free Survival as Evaluated By the Investigator in Accordance With Modified RECIST | Baseline up to disease progression or death whichever occurs first (up to 4 years) | PFS was defined as the time (in months) from initiation of study treatment to the first documented disease progression or death from any cause, whichever occurred first. PFS was evaluated by the investigator according to modified RECIST. |
| Percentage of Participants Alive 3 Years After Initiation of Treatment | Baseline up to Year 3 | The OS rate at 3 years, was defined as the percentage of participants remaining alive 3 years after initiation of study treatment. |
| Percentage of Participants With Objective Reponse as Assessed by the Investigator According to RECIST v1.1 | Baseline up to disease progression or death whichever occurs first (up to 4 years) | Objective response rate (ORR), according to RECIST v1.1, was defined as the percentage of participants with a confirmed best overall response (BOR), either complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1. |
| Percentage of Participants With Objective Reponse as Assessed by the Investigator According to Modified RECIST | Baseline up to disease progression or death whichever occurs first (up to 4 years) | The investigator-assessed ORR was defined as the proportion of participants whose confirmed BOR is either a PR or CR per modified RECIST. |
| Duration of Response as Assessed by the Investigator According to RECIST v.1.1 | From date of first objective response up to disease progression or death whichever occurs first (up to 4 years) | DOR was defined as the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first reported) to documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first, among participants who had a best overall response as CR or PR. |
| Duration of Response as Assessed by the Investigator According to Modified RECIST | From date of first objective response up to disease progression or death whichever occurs first (up to 4 years) | DOR was defined as the duration from the first tumor assessment that supports the participant's objective response (CR or PR, whichever is first recorded) to disease progression or death due to any cause, whichever occurred first. |
| EQ-5D-5L Questionnaire - VAS Scores | Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years) | The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. Values presented after baseline represent the change from baseline. |
Countries
Argentina, Brazil, China, Colombia, Costa Rica, Denmark, Greece, Guatemala, Italy, Latvia, Lebanon, Malaysia, Mexico, Morocco, Netherlands, Panama, Peru, Philippines, Poland, Slovenia, Spain, Sweden, United Arab Emirates, United Kingdom
Participant flow
Recruitment details
Participants were enrolled at 111 sites across 24 countries.
Pre-assignment details
Four enrolled participants died without receiving study treatment.
Participants by arm
| Arm | Count |
|---|---|
| Atezolizumab Participants with Stage IIIb or State IV NSCLC who had progressed after standard systemic chemotherapy received atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurred first). | 615 |
| Total | 615 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 470 |
| Overall Study | Lost to Follow-up | 18 |
| Overall Study | Physician Decision | 2 |
| Overall Study | Study Terminated By Sponsor | 79 |
| Overall Study | Withdrawal by Subject | 33 |
Baseline characteristics
| Characteristic | Atezolizumab |
|---|---|
| Age, Continuous | 63.7 Years STANDARD_DEVIATION 9.9 |
| ECOG Performance Status ECOG performance status 0 (fully active) | 193 Participants |
| ECOG Performance Status ECOG performance status 1 (restricted in physically strenuous activity) | 361 Participants |
| ECOG Performance Status ECOG performance status 2 (ambulatory and capable of selfcare; unable to carry out work activities) | 61 Participants |
| eGFR (mL/min/1.73 m^2) at baseline 15-<30 | 2 Participants |
| eGFR (mL/min/1.73 m^2) at baseline 30-<60 | 77 Participants |
| eGFR (mL/min/1.73 m^2) at baseline 60-<90 | 251 Participants |
| eGFR (mL/min/1.73 m^2) at baseline >=90 | 283 Participants |
| eGFR (mL/min/1.73 m^2) at baseline Missing | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 93 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 509 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 13 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 44 Participants |
| Race (NIH/OMB) Asian | 76 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 483 Participants |
| Region Asia | 70 Participants |
| Region EMEA (Europe, the Middle East, and Africa) | 455 Participants |
| Region LATAM (Latin America) | 90 Participants |
| Sex: Female, Male Female | 245 Participants |
| Sex: Female, Male Male | 370 Participants |
| Smoking Status Current | 115 Participants |
| Smoking Status Never | 127 Participants |
| Smoking Status Previous | 373 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 474 / 619 |
| other Total, other adverse events | 480 / 615 |
| serious Total, serious adverse events | 198 / 615 |
Outcome results
Primary
Percentage of Participants With Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unitended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a pharmaceutical product whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as a AEs.
Time frame: Baseline up to 4 years
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Atezolizumab | Percentage of Participants With Adverse Events | 564 Participants |
Secondary
Duration of Response as Assessed by the Investigator According to Modified RECIST
DOR was defined as the duration from the first tumor assessment that supports the participant's objective response (CR or PR, whichever is first recorded) to disease progression or death due to any cause, whichever occurred first.
Time frame: From date of first objective response up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab | Duration of Response as Assessed by the Investigator According to Modified RECIST | 20.5 Months |
Secondary
Duration of Response as Assessed by the Investigator According to RECIST v.1.1
DOR was defined as the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first reported) to documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first, among participants who had a best overall response as CR or PR.
Time frame: From date of first objective response up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab | Duration of Response as Assessed by the Investigator According to RECIST v.1.1 | 16.6 Months |
Secondary
EQ-5D-5L Questionnaire - Anxiety/Depression Item
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the anxiety/depression item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 042: No Problem | 90 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 114: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: Extreme Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: Invalid Response | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 006: No Problem | 267 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: No Problem | 334 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: Slight Problem | 163 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: Moderate Problems | 83 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: Severe Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: Extreme Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Baseline: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: No Problem | 296 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: Slight Problems | 157 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: Moderate Problems | 66 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Cycle 2 Day 1: Severe Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 144: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 147: No Problem | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 147: Slight Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 147: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 156: No Problem | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 156: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 156: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 165: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 165: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 165: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 165: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 174: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 174: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 183: No Problem | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 183: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 018: No Problem | 167 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 006: Slight Problems | 109 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 006: Moderate Problems | 49 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 006: Severe Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 006: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 012: No Problem | 190 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 012: Slight Problems | 102 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 012: Moderate Problems | 20 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 012: Severe Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 012: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 018: Slight Problems | 66 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 018: Moderate Problems | 22 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 018: Severe Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 018: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 024: No Problem | 140 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 024: Slight Problems | 62 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 024: Moderate Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 024: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 030: No Problem | 116 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 030: Slight Problems | 56 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 030: Moderate Problems | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 030: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 036: No Problem | 105 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 036: Slight Problems | 46 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 036: Moderate Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 036: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 042: Slight Problems | 42 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 042: Moderate Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 042: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 048: No Problem | 81 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 048: Slight Problems | 34 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 048: Moderate Problems | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 054: No Problem | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 054: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 054: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 057: No Problem | 68 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 057: Slight Problems | 18 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 057: Moderate Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 057: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 060: No Problem | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 060: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 060: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 066: No Problem | 63 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 066: Slight Problems | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 066: Moderate Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 066: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 066: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 072: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 072: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 072: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 075: No Problem | 51 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 075: Slight Problems | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 075: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 075: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 078: No Problem | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 078: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 078: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 084: No Problem | 45 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 084: Slight Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 084: Moderate Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 084: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 084: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 090: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 090: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 090: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 090: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 093: No Problem | 36 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 093: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 093: Moderate Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 093: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 096: No Problem | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 096: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 096: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 096: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 102: No Problem | 36 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 102: Slight Problems | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 102: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 102: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 108: No Problem | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 108: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 108: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 111: No Problem | 27 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 111: Slight Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 111: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 111: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 114: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 120: No Problem | 24 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 120: Slight Problems | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 120: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 126: No Problem | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 126: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 126: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 129: No Problem | 21 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 129: Slight Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 129: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 132: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 132: Moderate problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 138: No Problem | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 138: Slight Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 138: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Anxiety/Depression Item | Tumor Assessment Week 138: Invalid Response | 1 Participants |
Secondary
EQ-5D-5L Questionnaire - Pain/Discomfort Item
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the pain/discomfort item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 012: Extreme Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: No Problem | 123 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: Slight Problems | 88 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 036: Moderate Problems | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 036: Severe Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 036: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 042: No Problem | 68 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 042: Slight Problems | 51 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 042: Moderate Problems | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 042: Severe Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 129: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 165: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 165: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 006: Moderate Problems | 93 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 006: No Problem | 165 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 006: Slight Problems | 143 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 006: Severe Problems | 31 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 006: Extreme Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 012: No Problem | 125 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 012: Slight Problems | 116 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 012: Moderate Problems | 61 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 012: Severe Problems | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 042: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 048: No Problem | 64 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: Moderate Problems | 32 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: Severe Problems | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 018: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: No Problem | 101 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: Slight Problems | 74 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: Moderate Problems | 33 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: Severe Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 024: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 030: No Problem | 89 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 030: Slight Problems | 64 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 030: Moderate Problems | 25 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 030: Severe Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 036: No Problem | 85 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 036: Slight Problems | 51 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 048: Slight Problems | 41 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 066: Slight Problems | 27 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 048: Moderate Problems | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 048: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 048: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 054: No Problem | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 054: Slight Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 054: Moderate Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 057: No Problem | 53 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 129: Slight Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 129: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 132: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 057: Slight Problems | 27 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 057: Moderate Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 057: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 060: No Problem | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 060: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 060: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 066: No Problem | 48 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 066: Moderate Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 066: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 072: No Problem | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 072: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 072: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 075: No Problem | 45 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 075: Slight Problems | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 075: Moderate Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 075: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 078: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 078: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 078: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 084: No Problem | 41 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 084: Slight Problems | 18 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 084: Moderate Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 084: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 090: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 090: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 090: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 093: No Problem | 34 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 093: Slight Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 093: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 093: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 096: No Problem | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 096: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 096: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 102: No Problem | 33 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 102: Slight Problems | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 102: Moderate Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 102: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 108: No Problem | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 108: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 111: No Problem | 21 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 111: Slight Problems | 17 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 111: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 111: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 114: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 114: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 120: No Problem | 20 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 120: Slight Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 120: Moderate Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 126: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 126: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 129: No Problem | 17 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 138: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 138: No Problem | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 138: Slight Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 138: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 144: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 147: No Problem | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 147: Slight Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 147: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 156: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 156: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 156: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 165: No Problem | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 165: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 174: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 132: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 165: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 174: No Problem | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 174: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 183: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Tumor Assessment Week 183: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: No Problem | 206 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: Slight Problem | 216 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: Moderate Problems | 129 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: Severe Problems | 38 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: Extreme Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Baseline: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Cycle 2 Day 1: No Problem | 212 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Cycle 2 Day 1: Slight Problems | 165 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Cycle 2 Day 1: Moderate Problems | 117 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Cycle 2 Day 1: Severe Problems | 34 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Pain/Discomfort Item | Cycle 2 Day 1: Extreme Problems | 6 Participants |
Secondary
EQ-5D-5L Questionnaire - Self-Care Item
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the self-care item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 018: Slight Problems | 35 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 114: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: No Problem | 475 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: Slight Problem | 66 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: Moderate Problems | 44 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: Severe Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: Extreme Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Baseline: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: No Problem | 402 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: Slight Problems | 79 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: Moderate | 37 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: Severe Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: Extreme Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Cycle 2 Day 1: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 006: No Problem | 327 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 006: Slight Problems | 67 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 006: Moderate Problems | 33 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 006: Severe Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 006: Extreme Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 012: No Problem | 245 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 012: Slight Problems | 47 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 012: Moderate Problems | 20 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 012: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 012: Extreme Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 018: No Problem | 205 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 018: Moderate Problems | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 018: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 018: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: No Problem | 174 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: Slight Problems | 35 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: Moderate Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 024: Invalid Response | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 030: No Problem | 150 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 030: Slight Problems | 26 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 030: Moderate Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 030: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 036: No Problem | 129 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 036: Slight Problems | 24 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 036: Moderate Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 042: No Problem | 113 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 042: Slight Problems | 23 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 042: Moderate Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 048: No Problem | 99 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 048: Slight Problems | 18 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 048: Moderate Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 111: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 048: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 054: No Problem | 15 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 054: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 054: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 057: No Problem | 78 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 057: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 057: Moderate Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 057: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 060: No Problem | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 060: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 060: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 066: No Problem | 69 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 066: Slight Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 066: Moderate Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 072: No Problem | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 072: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 075: No Problem | 57 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 075: Slight Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 075: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 075: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 078: No Problem | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 078: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 078: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 084: No Problem | 51 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 084: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 084: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 084: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 090: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 090: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 090: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 093: No Problem | 44 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 093: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 093: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 093: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 096: No Problem | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 096: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 096: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 102: No Problem | 45 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 102: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 102: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 102: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 102: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 108: No Problem | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 108: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 111: No Problem | 33 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 111: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 114: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 120: No Problem | 30 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 120: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 120: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 126: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 126: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 129: No Problem | 26 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 129: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 129: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 132: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 132: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 138: No Problem | 23 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 138: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 144: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 147: No Problem | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 147: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 156: No Problem | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 156: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 165: No Problem | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 165: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 165: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 165: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 174: No Problem | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 174: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 183: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Self-Care Item | Tumor Assessment Week 183: Slight Problems | 2 Participants |
Secondary
EQ-5D-5L Questionnaire - Usual Activities Item
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the usual activities item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 084: Moderate Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 093: Moderate Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 102: Severe Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 012: Severe Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Baseline: No Problem | 297 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Baseline: Slight Problem | 164 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Baseline: Moderate Problems | 99 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Baseline: Severe Problems | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Baseline: Extreme Problems | 21 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Cycle 2 Day 1: No Problem | 257 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Cycle 2 Day 1: Slight Problems | 152 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Cycle 2 Day 1: Moderate Problems | 85 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Cycle 2 Day 1: Severe Problems | 24 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Cycle 2 Day 1: Extreme Problems | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 006: No Problem | 221 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 006: Slight Problems | 121 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 006: Moderate Problems | 69 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 006: Severe Problems | 14 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 006: Extreme Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 012: No Problem | 175 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 012: Slight Problems | 83 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 012: Moderate Problems | 47 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 012: Extreme Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 018: No Problem | 143 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 018: Slight Problems | 80 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 018: Moderate Problems | 29 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 018: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 018: Extreme Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: No Problem | 134 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: Slight Problems | 56 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: Moderate Problems | 22 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: Extreme Problems | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 024: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 030: No Problem | 124 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 030: Slight Problems | 43 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 030: Moderate Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 030: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 030: Extreme Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 036: No Problem | 107 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 036: Slight Problems | 38 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 036: Moderate Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 036: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 036: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 042: No Problem | 97 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 042: Slight Problems | 32 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 042: Moderate Problems | 11 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 042: Severe Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 042: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: No Problem | 81 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: Slight Problems | 31 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: Moderate Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: Severe Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 048: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 054: No Problem | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 054: Slight Problems | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 054: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 054: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 054: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: No Problem | 61 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: Slight Problems | 23 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: Moderate Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: Extreme Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 057: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 060: No Problem | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 060: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 060: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 060: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 066: No Problem | 58 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 066: Slight Problems | 19 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 066: Moderate Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 066: Severe Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 072: No Problem | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 072: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 072: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 072: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 075: No Problem | 47 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 075: Slight Problems | 21 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 075: Moderate Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 078: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 078: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 078: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 078: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 084: No Problem | 46 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 084: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 084: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 084: Extreme Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 090: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 090: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 090: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 093: No Problem | 36 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 093: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 093: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 096: No Problem | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 096: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 096: Severe Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 102: No Problem | 36 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 102: Slight Problems | 13 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 102: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 102: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 108: No Problem | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 108: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 111: No Problem | 25 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 111: Slight Problems | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 111: Moderate Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 111: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 114: Slight Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 114: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 120: No Problem | 27 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 120: Slight Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 120: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 126: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 126: Slight Problems | 3 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 129: No Problem | 22 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 129: Slight Problems | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 129: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 132: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 132: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 138: No Problem | 16 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 138: Slight Problems | 10 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 138: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 144: No Problem | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 147: No Problem | 12 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 147: Slight Problems | 7 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 147: Moderate Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 156: No Problem | 9 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 156: Slight Problems | 5 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 156: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 165: No Problem | 6 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 165: Slight Problems | 4 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 165: Moderate Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 165: Extreme Problems | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 165: Invalid Response | 1 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 174: No Problem | 8 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 174: Slight Problems | 2 Participants |
| Atezolizumab | EQ-5D-5L Questionnaire - Usual Activities Item | Tumor Assessment Week 183: Slight Problems | 3 Participants |
Secondary
EQ-5D-5L Questionnaire - VAS Scores
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. Values presented after baseline represent the change from baseline.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Cycle 2 Day 1 | -0.51 score on a scale | Standard Deviation 13.61 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 06 | -1.14 score on a scale | Standard Deviation 15.17 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 012 | 0.97 score on a scale | Standard Deviation 14.07 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 018 | 2.23 score on a scale | Standard Deviation 14.24 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 024 | 1.78 score on a scale | Standard Deviation 15.48 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 030 | 3.04 score on a scale | Standard Deviation 13.97 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 036 | 2.11 score on a scale | Standard Deviation 15.56 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 042 | 3.14 score on a scale | Standard Deviation 14.84 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 048 | 2.55 score on a scale | Standard Deviation 14.76 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 054 | 0.45 score on a scale | Standard Deviation 16.25 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 057 | 4.99 score on a scale | Standard Deviation 12.94 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 060 | 6.53 score on a scale | Standard Deviation 9.68 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 066 | 2.64 score on a scale | Standard Deviation 12.42 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 072 | 2.46 score on a scale | Standard Deviation 10.82 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 075 | 3.13 score on a scale | Standard Deviation 14.36 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 078 | 6.00 score on a scale | Standard Deviation 9.94 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 084 | 4.26 score on a scale | Standard Deviation 16.91 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 090 | 2.80 score on a scale | Standard Deviation 10.55 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 093 | 5.47 score on a scale | Standard Deviation 15.35 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 096 | 6.43 score on a scale | Standard Deviation 18.42 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 102 | 4.98 score on a scale | Standard Deviation 14.28 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 108 | 10.71 score on a scale | Standard Deviation 14.56 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 111 | 4.64 score on a scale | Standard Deviation 13.16 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 114 | 15.00 score on a scale | Standard Deviation 0 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 120 | 5.65 score on a scale | Standard Deviation 14.18 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 126 | 16.25 score on a scale | Standard Deviation 4.79 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 129 | 4.26 score on a scale | Standard Deviation 13.99 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 132 | 12.50 score on a scale | Standard Deviation 17.68 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 138 | 2.85 score on a scale | Standard Deviation 15.49 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 144 | -8.00 score on a scale | — |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 147 | 6.00 score on a scale | Standard Deviation 13.14 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 156 | 5.67 score on a scale | Standard Deviation 16.24 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 165 | 7.08 score on a scale | Standard Deviation 18.52 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 174 | 4.44 score on a scale | Standard Deviation 13.33 |
| Atezolizumab | EQ-5D-5L Questionnaire - VAS Scores | Tumor Assessment Week 183 | 5.33 score on a scale | Standard Deviation 21.57 |
Secondary
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13)
The EORTC QLQ-LC13 consisted of 13 items that address key lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related adverse effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. The dysphagia scale is multi-item, while the rest are single-item scales. The scales are linearly transformed so that each score has a range from 0 to 100. A high scale score represents a higher response level (e.g. a high score for global health status represents a high QoL). A high score for the symptom scale represents a high level of symptoms. A \>=10-point change in the EORTC scale score was perceived by participants as clinically significant. Values presented after baseline represent the change from baseline.
Time frame: Day 1 of first 3 cycles (21-day cycle), then every 6 weeks for 48 weeks; thereafter every 9 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 006 | 0.10 Units on a scale | Standard Deviation 9.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 012 | 0.15 Units on a scale | Standard Deviation 9.77 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 018 | -0.18 Units on a scale | Standard Deviation 8.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 024 | -0.67 Units on a scale | Standard Deviation 9.06 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 030 | -0.29 Units on a scale | Standard Deviation 10.31 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 036 | -1.79 Units on a scale | Standard Deviation 10.27 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 042 | 0.00 Units on a scale | Standard Deviation 11.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 048 | -0.46 Units on a scale | Standard Deviation 8.83 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 012 | -0.15 Units on a scale | Standard Deviation 16.63 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 057 | -0.58 Units on a scale | Standard Deviation 9.94 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 126 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Baseline | 24.82 Units on a scale | Standard Deviation 21.64 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Cycle (C) 02 Day (D) 01 | 2.41 Units on a scale | Standard Deviation 15.59 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 006 | 1.59 Units on a scale | Standard Deviation 18.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 012 | -0.62 Units on a scale | Standard Deviation 19.4 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 018 | -0.50 Units on a scale | Standard Deviation 17.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 024 | -2.84 Units on a scale | Standard Deviation 17.9 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 030 | -1.17 Units on a scale | Standard Deviation 21.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 036 | -3.91 Units on a scale | Standard Deviation 20.51 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 042 | -3.97 Units on a scale | Standard Deviation 19.1 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 048 | -3.65 Units on a scale | Standard Deviation 20.44 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 054 | 2.38 Units on a scale | Standard Deviation 16.98 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 057 | -5.25 Units on a scale | Standard Deviation 18.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 060 | -1.11 Units on a scale | Standard Deviation 11.05 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 066 | 1.09 Units on a scale | Standard Deviation 19.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 072 | 4.76 Units on a scale | Standard Deviation 30.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 075 | -2.22 Units on a scale | Standard Deviation 18.52 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 078 | 0.00 Units on a scale | Standard Deviation 42.31 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 084 | -2.92 Units on a scale | Standard Deviation 16.07 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 090 | -17.78 Units on a scale | Standard Deviation 12.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 093 | -3.57 Units on a scale | Standard Deviation 19.38 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 096 | 13.33 Units on a scale | Standard Deviation 27.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 102 | -5.95 Units on a scale | Standard Deviation 19.24 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 108 | -8.89 Units on a scale | Standard Deviation 26.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 111 | -6.88 Units on a scale | Standard Deviation 17.02 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 120 | -5.85 Units on a scale | Standard Deviation 14.04 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 126 | -18.52 Units on a scale | Standard Deviation 27.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 129 | -7.19 Units on a scale | Standard Deviation 13.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 132 | -22.22 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 138 | -1.71 Units on a scale | Standard Deviation 11.87 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 147 | -3.70 Units on a scale | Standard Deviation 7.86 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 156 | 6.94 Units on a scale | Standard Deviation 23.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 165 | 3.70 Units on a scale | Standard Deviation 23.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea: Tumor Assessment Wk 183 | -11.11 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Baseline | 33.84 Units on a scale | Standard Deviation 25.94 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: C2D1 | 0.80 Units on a scale | Standard Deviation 21.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 006 | -0.68 Units on a scale | Standard Deviation 24.84 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 012 | -4.44 Units on a scale | Standard Deviation 28.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 018 | -7.88 Units on a scale | Standard Deviation 25.61 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 024 | -7.83 Units on a scale | Standard Deviation 26.95 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 030 | -7.18 Units on a scale | Standard Deviation 26.3 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 036 | -9.32 Units on a scale | Standard Deviation 25.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 042 | -13.18 Units on a scale | Standard Deviation 25.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 048 | -9.26 Units on a scale | Standard Deviation 30.76 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 054 | -2.38 Units on a scale | Standard Deviation 24.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 057 | -13.22 Units on a scale | Standard Deviation 28.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 060 | -9.09 Units on a scale | Standard Deviation 21.56 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 066 | -10.69 Units on a scale | Standard Deviation 28.32 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 072 | -4.76 Units on a scale | Standard Deviation 23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 075 | -18.33 Units on a scale | Standard Deviation 28.19 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 078 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 084 | -16.67 Units on a scale | Standard Deviation 31.72 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 090 | -16.67 Units on a scale | Standard Deviation 18.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 093 | -16.67 Units on a scale | Standard Deviation 30.77 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 096 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 102 | -23.81 Units on a scale | Standard Deviation 25.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 108 | -6.67 Units on a scale | Standard Deviation 27.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 111 | -11.11 Units on a scale | Standard Deviation 30.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 120 | -12.28 Units on a scale | Standard Deviation 29.84 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 126 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 129 | -11.76 Units on a scale | Standard Deviation 26.2 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 138 | -14.29 Units on a scale | Standard Deviation 31.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 144 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 147 | -22.22 Units on a scale | Standard Deviation 40.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 156 | -12.50 Units on a scale | Standard Deviation 53.27 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 174 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Coughing: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Baseline | 3.02 Units on a scale | Standard Deviation 10.15 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: C2D1 | 0.60 Units on a scale | Standard Deviation 9.05 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 054 | 0.00 Units on a scale | Standard Deviation 13.07 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 066 | -2.52 Units on a scale | Standard Deviation 8.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 072 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 075 | -3.33 Units on a scale | Standard Deviation 10.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 057 | 0.00 Units on a scale | Standard Deviation 10.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 060 | 0.00 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 102 | 1.19 Units on a scale | Standard Deviation 6.3 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 102 | -2.38 Units on a scale | Standard Deviation 8.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 108 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 111 | -3.17 Units on a scale | Standard Deviation 10.03 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 114 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 120 | -1.75 Units on a scale | Standard Deviation 13.49 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 126 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 129 | -1.96 Units on a scale | Standard Deviation 14.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 138 | -2.38 Units on a scale | Standard Deviation 15.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 147 | 0.00 Units on a scale | Standard Deviation 16.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 156 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 174 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Baseline | 3.58 Units on a scale | Standard Deviation 12.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: C2D1 | 0.67 Units on a scale | Standard Deviation 15.76 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 006 | 0.49 Units on a scale | Standard Deviation 16.95 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 012 | 0.00 Units on a scale | Standard Deviation 16.55 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 018 | -0.73 Units on a scale | Standard Deviation 14 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 024 | -1.13 Units on a scale | Standard Deviation 14.24 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 030 | -2.03 Units on a scale | Standard Deviation 14.16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 036 | -2.54 Units on a scale | Standard Deviation 15.02 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 042 | -1.57 Units on a scale | Standard Deviation 16.99 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 048 | -4.29 Units on a scale | Standard Deviation 15.97 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 054 | 2.56 Units on a scale | Standard Deviation 16.45 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 057 | -1.75 Units on a scale | Standard Deviation 11.65 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 060 | -3.33 Units on a scale | Standard Deviation 10.54 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 066 | -2.56 Units on a scale | Standard Deviation 14.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 072 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 075 | -2.50 Units on a scale | Standard Deviation 13.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 078 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 084 | -1.75 Units on a scale | Standard Deviation 13.3 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 090 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 093 | 2.38 Units on a scale | Standard Deviation 8.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 096 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 108 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 111 | 3.17 Units on a scale | Standard Deviation 10.03 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 114 | 33.33 Units on a scale | Standard Deviation 47.14 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 120 | 7.02 Units on a scale | Standard Deviation 17.84 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 126 | 11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 129 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 132 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 138 | 2.38 Units on a scale | Standard Deviation 8.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 147 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 156 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Sore mouth: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Baseline | 5.46 Units on a scale | Standard Deviation 14.73 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: C2D1 | 0.20 Units on a scale | Standard Deviation 13.92 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 006 | -1.38 Units on a scale | Standard Deviation 13.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 018 | 0.74 Units on a scale | Standard Deviation 16.08 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 024 | -1.59 Units on a scale | Standard Deviation 11.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 030 | -1.46 Units on a scale | Standard Deviation 10.3 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 036 | -1.83 Units on a scale | Standard Deviation 16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 042 | -1.59 Units on a scale | Standard Deviation 13.6 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 048 | -0.48 Units on a scale | Standard Deviation 15.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 054 | -2.56 Units on a scale | Standard Deviation 9.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 078 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 084 | -2.63 Units on a scale | Standard Deviation 9.11 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 090 | 5.56 Units on a scale | Standard Deviation 13.61 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 093 | 1.19 Units on a scale | Standard Deviation 14.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Haemoptysis: Tumor Assessment Wk 096 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 060 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 066 | -1.28 Units on a scale | Standard Deviation 11.36 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 072 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 075 | 0.00 Units on a scale | Standard Deviation 15.1 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 078 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 084 | -2.63 Units on a scale | Standard Deviation 11.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 090 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 093 | -2.38 Units on a scale | Standard Deviation 8.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 096 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 102 | -2.38 Units on a scale | Standard Deviation 8.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 108 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 111 | 0.00 Units on a scale | Standard Deviation 10.54 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 114 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 120 | -1.75 Units on a scale | Standard Deviation 7.65 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 129 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 138 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 147 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 156 | 4.17 Units on a scale | Standard Deviation 11.79 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 120 | -1.75 Units on a scale | Standard Deviation 13.49 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dysphagia: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Baseline | 17.77 Units on a scale | Standard Deviation 26.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: C2D1 | -0.20 Units on a scale | Standard Deviation 22.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 006 | -0.58 Units on a scale | Standard Deviation 21.8 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 012 | 0.15 Units on a scale | Standard Deviation 24.2 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 018 | -2.56 Units on a scale | Standard Deviation 26.56 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 024 | -3.15 Units on a scale | Standard Deviation 25.3 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 030 | -3.19 Units on a scale | Standard Deviation 24.17 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 036 | -6.23 Units on a scale | Standard Deviation 25.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 042 | -7.45 Units on a scale | Standard Deviation 28.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 048 | -8.92 Units on a scale | Standard Deviation 27.58 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 054 | -7.69 Units on a scale | Standard Deviation 19.97 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 057 | -6.32 Units on a scale | Standard Deviation 20.19 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 060 | -13.33 Units on a scale | Standard Deviation 17.21 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 066 | -3.85 Units on a scale | Standard Deviation 22.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 072 | -4.76 Units on a scale | Standard Deviation 23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 075 | -10.83 Units on a scale | Standard Deviation 26.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 078 | -6.67 Units on a scale | Standard Deviation 27.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 084 | -9.65 Units on a scale | Standard Deviation 28.9 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 090 | 0.00 Units on a scale | Standard Deviation 21.08 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 093 | -5.95 Units on a scale | Standard Deviation 30.16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 096 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 102 | -8.33 Units on a scale | Standard Deviation 26.64 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 108 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 111 | -14.29 Units on a scale | Standard Deviation 34.27 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 120 | -14.04 Units on a scale | Standard Deviation 32.04 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 126 | -11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 129 | -7.84 Units on a scale | Standard Deviation 25.08 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 138 | -19.05 Units on a scale | Standard Deviation 33.88 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 147 | -22.22 Units on a scale | Standard Deviation 40.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 156 | -12.50 Units on a scale | Standard Deviation 50.2 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 165 | 11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 174 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Peripheral neuropathy: Tumor Assessment Wk 183 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Baseline | 13.95 Units on a scale | Standard Deviation 27.14 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: C2D1 | -5.64 Units on a scale | Standard Deviation 24.32 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 006 | -4.31 Units on a scale | Standard Deviation 24.84 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 012 | -5.98 Units on a scale | Standard Deviation 25.39 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 018 | -6.85 Units on a scale | Standard Deviation 24.59 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 024 | -8.11 Units on a scale | Standard Deviation 24.16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 030 | -6.96 Units on a scale | Standard Deviation 25.93 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 036 | -6.52 Units on a scale | Standard Deviation 25.79 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 042 | -6.67 Units on a scale | Standard Deviation 26.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 048 | -7.51 Units on a scale | Standard Deviation 26.55 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 054 | 2.56 Units on a scale | Standard Deviation 9.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 057 | -6.43 Units on a scale | Standard Deviation 27.77 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 060 | 0.00 Units on a scale | Standard Deviation 15.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 066 | -6.41 Units on a scale | Standard Deviation 26.44 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 072 | 9.52 Units on a scale | Standard Deviation 16.27 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 075 | -6.67 Units on a scale | Standard Deviation 27.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 078 | 13.33 Units on a scale | Standard Deviation 18.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 084 | -6.14 Units on a scale | Standard Deviation 26.68 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 090 | 5.56 Units on a scale | Standard Deviation 13.61 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 093 | -4.76 Units on a scale | Standard Deviation 28.28 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 096 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 102 | -4.76 Units on a scale | Standard Deviation 26.78 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 108 | 20.00 Units on a scale | Standard Deviation 18.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 111 | -3.17 Units on a scale | Standard Deviation 27.7 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 114 | 16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 120 | 3.51 Units on a scale | Standard Deviation 29.18 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 126 | 22.22 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 129 | 5.88 Units on a scale | Standard Deviation 17.62 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 138 | -4.76 Units on a scale | Standard Deviation 28.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 147 | -7.41 Units on a scale | Standard Deviation 36.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 156 | -4.17 Units on a scale | Standard Deviation 45.21 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Alopecia: Tumor Assessment Wk 183 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 126 | -11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 129 | -1.96 Units on a scale | Standard Deviation 14.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Baseline | 14.20 Units on a scale | Standard Deviation 21.62 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: C2D1 | 0.13 Units on a scale | Standard Deviation 19.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 006 | 0.10 Units on a scale | Standard Deviation 23.99 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 138 | 7.69 Units on a scale | Standard Deviation 19.97 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 012 | -0.75 Units on a scale | Standard Deviation 22.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 018 | -1.12 Units on a scale | Standard Deviation 18.38 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 024 | -2.74 Units on a scale | Standard Deviation 18.16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 147 | 7.41 Units on a scale | Standard Deviation 14.7 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 030 | -1.77 Units on a scale | Standard Deviation 20.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 156 | 20.83 Units on a scale | Standard Deviation 17.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 036 | -2.96 Units on a scale | Standard Deviation 20.39 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 042 | -2.41 Units on a scale | Standard Deviation 20.02 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 048 | -4.35 Units on a scale | Standard Deviation 22.8 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 054 | 0.00 Units on a scale | Standard Deviation 20.1 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 057 | -6.06 Units on a scale | Standard Deviation 21.36 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 060 | 7.41 Units on a scale | Standard Deviation 22.22 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 066 | -3.33 Units on a scale | Standard Deviation 20.48 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 072 | -14.29 Units on a scale | Standard Deviation 17.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 075 | -6.14 Units on a scale | Standard Deviation 18.75 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 078 | -16.67 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 084 | -7.41 Units on a scale | Standard Deviation 16.16 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 090 | -6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 093 | -1.33 Units on a scale | Standard Deviation 15.15 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 096 | -8.33 Units on a scale | Standard Deviation 16.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 102 | -8.97 Units on a scale | Standard Deviation 15.08 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 108 | -13.33 Units on a scale | Standard Deviation 18.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 111 | -5.00 Units on a scale | Standard Deviation 16.31 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 114 | -33.33 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 165 | 11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 120 | -7.41 Units on a scale | Standard Deviation 18.28 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 126 | -11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 129 | -6.25 Units on a scale | Standard Deviation 18.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 183 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Baseline | 27.31 Units on a scale | Standard Deviation 26.59 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: C2D1 | 2.52 Units on a scale | Standard Deviation 21.43 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 006 | 1.18 Units on a scale | Standard Deviation 23.65 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 012 | -1.21 Units on a scale | Standard Deviation 26.37 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 132 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 138 | -5.13 Units on a scale | Standard Deviation 22.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 018 | -1.29 Units on a scale | Standard Deviation 24.94 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 144 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 147 | -4.17 Units on a scale | Standard Deviation 21.36 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 156 | -9.52 Units on a scale | Standard Deviation 16.27 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 165 | 11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in chest: Tumor Assessment Wk 183 | 33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Baseline | 16.09 Units on a scale | Standard Deviation 24.63 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: C2D1 | 1.81 Units on a scale | Standard Deviation 21.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 006 | -0.30 Units on a scale | Standard Deviation 23.85 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 012 | 0.75 Units on a scale | Standard Deviation 24.09 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 018 | 3.15 Units on a scale | Standard Deviation 28.78 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 024 | -0.68 Units on a scale | Standard Deviation 23.56 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 030 | 0.00 Units on a scale | Standard Deviation 25.86 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 036 | -2.20 Units on a scale | Standard Deviation 22.11 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 042 | -1.19 Units on a scale | Standard Deviation 24.51 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 048 | -2.38 Units on a scale | Standard Deviation 24.95 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 054 | 2.56 Units on a scale | Standard Deviation 21.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 057 | 1.72 Units on a scale | Standard Deviation 26.8 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 060 | -6.67 Units on a scale | Standard Deviation 21.08 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 066 | 0.64 Units on a scale | Standard Deviation 21.38 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 072 | 4.76 Units on a scale | Standard Deviation 23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 075 | -4.27 Units on a scale | Standard Deviation 23.17 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 078 | 16.67 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 084 | -9.01 Units on a scale | Standard Deviation 23.11 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 090 | 0.00 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 093 | -9.88 Units on a scale | Standard Deviation 20.29 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 096 | -8.33 Units on a scale | Standard Deviation 16.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 102 | -4.94 Units on a scale | Standard Deviation 20.05 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 108 | 0.00 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 111 | -6.35 Units on a scale | Standard Deviation 20.05 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 114 | 16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 120 | -7.02 Units on a scale | Standard Deviation 21.02 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 126 | 22.22 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 129 | -7.84 Units on a scale | Standard Deviation 18.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 138 | -11.90 Units on a scale | Standard Deviation 16.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 144 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 147 | -11.11 Units on a scale | Standard Deviation 16.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 156 | -12.50 Units on a scale | Standard Deviation 17.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 165 | -11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 174 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in arm or shoulder: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Baseline | 25.46 Units on a scale | Standard Deviation 30.26 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: C2D1 | -0.49 Units on a scale | Standard Deviation 27.84 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 006 | 1.12 Units on a scale | Standard Deviation 31.8 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 012 | 0.93 Units on a scale | Standard Deviation 28.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 018 | -1.19 Units on a scale | Standard Deviation 23.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 024 | -1.41 Units on a scale | Standard Deviation 23.11 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 030 | -0.62 Units on a scale | Standard Deviation 21.95 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 036 | -4.17 Units on a scale | Standard Deviation 19.45 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 042 | -4.17 Units on a scale | Standard Deviation 24.52 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 048 | -0.98 Units on a scale | Standard Deviation 23.72 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 054 | 11.11 Units on a scale | Standard Deviation 16.41 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 057 | -5.23 Units on a scale | Standard Deviation 20.41 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 060 | 3.70 Units on a scale | Standard Deviation 11.11 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 066 | -0.67 Units on a scale | Standard Deviation 27.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 072 | 4.76 Units on a scale | Standard Deviation 12.6 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 075 | -2.70 Units on a scale | Standard Deviation 25.31 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 078 | 16.67 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 084 | -3.92 Units on a scale | Standard Deviation 26.92 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 090 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 093 | -10.26 Units on a scale | Standard Deviation 22.65 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 096 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 024 | -3.83 Units on a scale | Standard Deviation 26.23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 030 | -2.32 Units on a scale | Standard Deviation 26.39 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 102 | -8.97 Units on a scale | Standard Deviation 22.23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 108 | 6.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 111 | -8.33 Units on a scale | Standard Deviation 28.36 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 114 | 16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 120 | -3.92 Units on a scale | Standard Deviation 20.01 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 126 | 33.33 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 129 | -6.25 Units on a scale | Standard Deviation 18.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 132 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 138 | -10.26 Units on a scale | Standard Deviation 21.01 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 147 | -12.50 Units on a scale | Standard Deviation 24.8 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 156 | -14.29 Units on a scale | Standard Deviation 17.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 165 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Pain in other parts: Tumor Assessment Wk 183 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Baseline | 10.47 Units on a scale | Standard Deviation 19.79 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: C2D1 | 2.53 Units on a scale | Standard Deviation 19.17 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 006 | 1.68 Units on a scale | Standard Deviation 20.59 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 012 | 1.65 Units on a scale | Standard Deviation 19.61 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 018 | 1.83 Units on a scale | Standard Deviation 17.07 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 024 | -0.23 Units on a scale | Standard Deviation 15.9 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 030 | 2.03 Units on a scale | Standard Deviation 21.76 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 036 | 0.37 Units on a scale | Standard Deviation 20.18 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 042 | -0.40 Units on a scale | Standard Deviation 19.01 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 048 | 0.95 Units on a scale | Standard Deviation 17.92 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 054 | 2.38 Units on a scale | Standard Deviation 8.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 057 | -2.38 Units on a scale | Standard Deviation 19.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 060 | 0.00 Units on a scale | Standard Deviation 0 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 066 | 3.27 Units on a scale | Standard Deviation 17.96 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 072 | 9.52 Units on a scale | Standard Deviation 31.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 075 | -0.83 Units on a scale | Standard Deviation 17.68 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 078 | 20.00 Units on a scale | Standard Deviation 50.55 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 084 | -0.88 Units on a scale | Standard Deviation 16.42 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 090 | 11.11 Units on a scale | Standard Deviation 45.54 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 093 | 4.76 Units on a scale | Standard Deviation 23.51 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 096 | 13.33 Units on a scale | Standard Deviation 29.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 102 | -1.19 Units on a scale | Standard Deviation 16.93 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 108 | -6.67 Units on a scale | Standard Deviation 27.89 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 111 | -1.59 Units on a scale | Standard Deviation 16.59 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Resting: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 036 | -3.94 Units on a scale | Standard Deviation 27.74 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 042 | -3.88 Units on a scale | Standard Deviation 25.78 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 048 | -6.48 Units on a scale | Standard Deviation 27.77 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 054 | 2.38 Units on a scale | Standard Deviation 27.62 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 057 | -7.02 Units on a scale | Standard Deviation 23.35 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 060 | -3.03 Units on a scale | Standard Deviation 17.98 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 066 | -1.89 Units on a scale | Standard Deviation 25.67 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 072 | 4.76 Units on a scale | Standard Deviation 29.99 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 075 | -4.17 Units on a scale | Standard Deviation 22.88 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 078 | -6.67 Units on a scale | Standard Deviation 54.77 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 084 | -6.14 Units on a scale | Standard Deviation 23.06 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 090 | -5.56 Units on a scale | Standard Deviation 38.97 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 093 | -5.95 Units on a scale | Standard Deviation 24.09 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 096 | 13.33 Units on a scale | Standard Deviation 38.01 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 102 | -8.33 Units on a scale | Standard Deviation 26.64 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 108 | -20.00 Units on a scale | Standard Deviation 29.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 111 | -9.52 Units on a scale | Standard Deviation 26.13 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 120 | -7.02 Units on a scale | Standard Deviation 21.02 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 126 | -33.33 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 129 | -9.80 Units on a scale | Standard Deviation 19.6 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 132 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 138 | -2.38 Units on a scale | Standard Deviation 24.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 147 | -3.70 Units on a scale | Standard Deviation 26.06 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 156 | 4.17 Units on a scale | Standard Deviation 37.53 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 165 | 11.11 Units on a scale | Standard Deviation 38.49 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Walking: Tumor Assessment Wk 183 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Baseline | 37.12 Units on a scale | Standard Deviation 29.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: C2D1 | 2.23 Units on a scale | Standard Deviation 22.71 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 006 | 1.39 Units on a scale | Standard Deviation 26.23 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 012 | -1.66 Units on a scale | Standard Deviation 27.2 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 018 | -2.04 Units on a scale | Standard Deviation 26.17 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 024 | -4.73 Units on a scale | Standard Deviation 24.9 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 030 | -2.61 Units on a scale | Standard Deviation 28.66 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 036 | -6.81 Units on a scale | Standard Deviation 29.72 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 042 | -5.81 Units on a scale | Standard Deviation 26.17 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 048 | -3.70 Units on a scale | Standard Deviation 29.37 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 054 | 2.38 Units on a scale | Standard Deviation 24.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 057 | -6.90 Units on a scale | Standard Deviation 27.75 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 060 | -3.03 Units on a scale | Standard Deviation 17.98 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 066 | 1.89 Units on a scale | Standard Deviation 26.49 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 072 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 075 | -1.67 Units on a scale | Standard Deviation 28.19 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 078 | -13.33 Units on a scale | Standard Deviation 29.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 084 | -1.75 Units on a scale | Standard Deviation 24.44 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 090 | -26.67 Units on a scale | Standard Deviation 14.91 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 093 | -9.52 Units on a scale | Standard Deviation 23.76 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 096 | 13.33 Units on a scale | Standard Deviation 29.81 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 102 | -8.33 Units on a scale | Standard Deviation 26.64 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 108 | 0.00 Units on a scale | Standard Deviation 33.33 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 111 | -9.52 Units on a scale | Standard Deviation 23.9 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 114 | -16.67 Units on a scale | Standard Deviation 23.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 120 | -8.77 Units on a scale | Standard Deviation 18.73 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 126 | -11.11 Units on a scale | Standard Deviation 38.49 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 129 | -9.80 Units on a scale | Standard Deviation 22.87 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 132 | -33.33 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 138 | -11.90 Units on a scale | Standard Deviation 24.83 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 144 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 147 | -14.81 Units on a scale | Standard Deviation 17.57 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 156 | -4.17 Units on a scale | Standard Deviation 27.82 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 165 | -11.11 Units on a scale | Standard Deviation 19.25 |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 174 | 0.00 Units on a scale | — |
| Atezolizumab | European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Supplemental Lung Cancer Module (EORTC QLQ-LC13) | Dyspnoea at Climbing Stairs: Tumor Assessment Wk 183 | -33.33 Units on a scale | — |
Secondary
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item
The EQ-5D-5L was a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score for use in health economic analysis. The EQ-5D-5L has two components: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a Visual Analogue Scale (VAS) that measures health state. Each item was rated from 1 (no problems) to 5 (extreme problems). Categories with non-zero values are reported here. Number of participants who rated the mobility item ranging from 1-5 are reported. Participants who had a invalid response were presented under the category 'Invalid Response'.
Time frame: Day 1 of first 2 cycles (21-day cycle), then every 6 weeks for 54 weeks; thereafter every 3 weeks or 6 weeks until disease progression or until treatment discontinuation (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. Number analyzed are unique number of participants out of all the assessed participants who were evaluable at specified timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: No Problem | 328 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: Slight Problem | 146 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: Moderate Problems | 97 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: Severe Problems | 24 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Baseline: Invalid Response | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: No Problem | 274 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: Slight Problems | 145 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: Moderate Problems | 84 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: Severe Problems | 26 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: Extreme Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Cycle 2 Day 1: Invalid Response | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 006: No Problem | 229 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 006: Slight Problems | 121 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 006: Moderate Problems | 69 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 006: Severe Problems | 16 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 006: Extreme Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: No Problem | 183 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: Slight Problems | 75 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: Moderate Problems | 48 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: Severe Problems | 10 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: Extreme Problems | 5 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 012: Invalid Response | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 018: No Problem | 153 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 018: Slight Problems | 66 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 018: Moderate Problems | 27 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 018: Severe Problems | 11 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 018: Extreme Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: No Problem | 131 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: Slight Problems | 56 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: Moderate Problems | 22 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: Severe Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: Extreme Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 024: Invalid Response | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 030: No Problem | 124 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 030: Slight Problems | 41 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 030: Moderate Problems | 14 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 030: Severe Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 030: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 036: No Problem | 110 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 036: Slight Problems | 31 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 036: Moderate Problems | 20 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 036: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 042: No Problem | 88 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 042: Slight Problems | 39 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 042: Moderate Problems | 14 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 042: Severe Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 048: No Problem | 75 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 048: Slight Problems | 32 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 048: Moderate Problems | 16 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 048: Severe Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 048: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 054: No Problem | 11 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 054: Slight Problems | 6 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 054: Moderate Problems | 5 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 054: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 057: No Problem | 64 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 057: Slight Problems | 20 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 057: Moderate Problems | 8 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 057: Severe Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 057: Extreme Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 060: No Problem | 10 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 060: Slight Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 060: Moderate Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 060: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 066: No Problem | 56 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 066: Slight Problems | 20 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 066: Moderate Problems | 9 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 066: Severe Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 066: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 072: No Problem | 7 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 072: Slight Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 072: Moderate Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 075: No Problem | 45 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 075: Slight Problems | 20 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 075: Moderate Problems | 7 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 075: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 078: No Problem | 6 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 078: Slight Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 078: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 084: No Problem | 47 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 084: Slight Problems | 12 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 084: Moderate Problems | 6 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 084: Severe Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 090: No Problem | 7 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 090: Slight Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 090: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 093: No Problem | 34 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 093: Slight Problems | 16 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 093: Moderate Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 093: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 096: No Problem | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 096: Slight Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 096: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 102: No Problem | 33 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 102: Slight Problems | 16 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 102: Moderate Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 102: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 102: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 108: No Problem | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 108: Slight Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 108: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 111: No Problem | 25 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 111: Slight Problems | 13 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 111: Moderate Problems | 2 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 111: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 114: Slight Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 114: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 120: No Problem | 22 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 120: Slight Problems | 14 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 120: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 120: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 126: No Problem | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 126: Slight Problems | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 129: No Problem | 19 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 129: Slight Problems | 11 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 129: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 129: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 132: No Problem | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 132: Slight Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 138: No Problem | 17 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 138: Slight Problems | 10 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 138: Extreme Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 144: No Problem | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 147: No Problem | 14 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 147: Slight Problems | 6 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 147: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 156: No Problem | 8 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 156: Slight Problems | 5 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 156: Moderate Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 156: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 165: No Problem | 3 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 165: Slight Problems | 8 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 165: Severe Problems | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 165: Invalid Response | 1 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 174: No Problem | 6 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 174: Slight Problems | 4 Participants |
| Atezolizumab | EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire - Mobility Item | Tumor Assessment Week 183: Slight Problems | 3 Participants |
Secondary
Overall Survival (OS)
OS was defined as the time (in months) from initiation of study treatment to death from any cause.
Time frame: Baseline up to death (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab | Overall Survival (OS) | 11.2 Months |
Secondary
Percentage of Participants Alive 2 Years After Initiation of Treatment
The overall survival (OS) rate at 2 years, was defined as the percentage of participants remaining alive 2 years after initiation of study treatment.
Time frame: Baseline up to Year 2
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab | Percentage of Participants Alive 2 Years After Initiation of Treatment | 26.7 Percentage of Participants |
Secondary
Percentage of Participants Alive 3 Years After Initiation of Treatment
The OS rate at 3 years, was defined as the percentage of participants remaining alive 3 years after initiation of study treatment.
Time frame: Baseline up to Year 3
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab | Percentage of Participants Alive 3 Years After Initiation of Treatment | 19.6 Percentage of Participants |
Secondary
Percentage of Participants With Objective Reponse as Assessed by the Investigator According to Modified RECIST
The investigator-assessed ORR was defined as the proportion of participants whose confirmed BOR is either a PR or CR per modified RECIST.
Time frame: Baseline up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab | Percentage of Participants With Objective Reponse as Assessed by the Investigator According to Modified RECIST | 12.4 Percentage of Participants |
Secondary
Percentage of Participants With Objective Reponse as Assessed by the Investigator According to RECIST v1.1
Objective response rate (ORR), according to RECIST v1.1, was defined as the percentage of participants with a confirmed best overall response (BOR), either complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1.
Time frame: Baseline up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab | Percentage of Participants With Objective Reponse as Assessed by the Investigator According to RECIST v1.1 | 11.5 Percentage of Participants |
Secondary
Progression-Free Survival as Evaluated By the Investigator in Accordance With Modified RECIST
PFS was defined as the time (in months) from initiation of study treatment to the first documented disease progression or death from any cause, whichever occurred first. PFS was evaluated by the investigator according to modified RECIST.
Time frame: Baseline up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. This was a single-arm study. The study population was participants with Stage IIIB or Stage IV NSCLC. The primary objective of this study was to understand the safety in this participant population (without distinction of Stage IIIB and IV) and it was not planned to analyze them separately as per the protocol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab | Progression-Free Survival as Evaluated By the Investigator in Accordance With Modified RECIST | 3.7 Months |
Secondary
Progression-Free Survival (PFS) as Evaluated By the Investigator in Accordance With Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v.1.1)
PFS was defined as the time (in months) from initiation of study treatment to the first documented disease progression or death from any cause, whichever occurred first. PFS was evaluated by the investigator according to RECIST v1.1.
Time frame: Baseline up to disease progression or death whichever occurs first (up to 4 years)
Population: The safety population was based on all participants who received any dose of atezolizumab during the study treatment. This was a single-arm study. The study population was participants with Stage IIIB or Stage IV NSCLC. The primary objective of this study was to understand the safety in this participant population (without distinction of Stage IIIB and IV) and it was not planned to analyze them separately as per the protocol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab | Progression-Free Survival (PFS) as Evaluated By the Investigator in Accordance With Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v.1.1) | 2.7 Months |